1801 — Innovent Biologics Income Statement
0.000.00%
Last trade - 00:00
- HK$72.09bn
- HK$66.29bn
- CNY6.21bn
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,048 | 3,844 | 4,270 | 4,556 | 6,206 |
Cost of Revenue | |||||
Gross Profit | 923 | 3,456 | 3,764 | 3,625 | 5,070 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,708 | 4,634 | 6,849 | 6,625 | 7,252 |
Operating Profit | -1,660 | -790 | -2,579 | -2,069 | -1,046 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1,720 | -859 | -2,642 | -2,170 | -1,144 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,720 | -998 | -2,729 | -2,179 | -1,028 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1,720 | -998 | -2,729 | -2,179 | -1,028 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,720 | -998 | -2,729 | -2,179 | -1,028 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.46 | -0.735 | -1.87 | -1.46 | -0.611 |